公开(公告)号：US20090203922A1

公开(公告)日：2009-08-13

申请号：US12085258

申请日：2006-11-17

申请人： Kevin Michael Belyk ,  Benjamin Dorner ,  Frederick Hartner ,  Naoki Yoshikawa ,  John Limanto ,  Lushi Tan ,  Enrique Vazquez ,  Joseph Payack

发明人： Kevin Michael Belyk ,  Benjamin Dorner ,  Frederick Hartner ,  Naoki Yoshikawa ,  John Limanto ,  Lushi Tan ,  Enrique Vazquez ,  Joseph Payack

IPC分类号： C07D235/02

CPC分类号： C07D235/02

摘要： The present invention describes an efficient and economical process for the preparation of a 2,3-disubstituted 2-phenyl-1h-phenantrho[9,10-d]imidazole derivative that is useful for the large scale production of material for preclinical and clinical use. The process of the present invention represents a convergent approach to generate the 2,3-disubstituted 2-phenyl-1h-phenantrho[9,10-d]imidazole derivative in high overall yield. The compound made by the process of the invention is an inhibitor of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and is therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain.

摘要翻译： 本发明描述了一种用于制备2,3-二取代的2-苯基-1h-异丁基[9,10-d]咪唑衍生物的有效和经济的方法，其用于大规模生产用于临床前和临床应用的材料 。 本发明的方法代表以高的总产率生成2,3-二取代的2-苯基-1h-异丁基[9,10-d]咪唑衍生物的收敛方法。 通过本发明方法制备的化合物是微粒体前列腺素E合酶-1（mPGES-1）酶的抑制剂，因此可用于治疗各种疾病或病症的疼痛和/或炎症，例如骨关节炎，类风湿病 关节炎和急性或慢性疼痛。

公开(公告)号：US20080064635A1

公开(公告)日：2008-03-13

申请号：US11771417

申请日：2007-06-29

申请人： Ricardo Rueda ,  Alejandro Barranco ,  Maria Ramirez ,  Enrique Vazquez ,  Eduardo Valverde ,  Pedro Prieto ,  Margaret Dohnalek

发明人： Ricardo Rueda ,  Alejandro Barranco ,  Maria Ramirez ,  Enrique Vazquez ,  Eduardo Valverde ,  Pedro Prieto ,  Margaret Dohnalek

IPC分类号： A61K38/16 ,  A23D7/005 ,  A61P43/00

CPC分类号： A61K33/00 ,  A23L33/12 ,  A23L33/19 ,  A23L33/40 ,  A61K31/202 ,  A61K31/28 ,  A61K31/685 ,  A61K31/7008 ,  A61K31/7032 ,  A61K38/00 ,  A61K45/06

摘要： Disclosed are infant formulas comprising at least about 6.5 g/L, on an as-fed basis, of an enriched whey protein concentrate, at least about 0.13% docosahexaenoic acid by weight of total fatty acids, and at least about 0.25% arachidonic acid by weight of total fatty acids. The formulas also typically include at least about 5 mg/L of gangliosides, at least about 150 mg/L of phospholipids, and at least about 70 mg/L of total sialic acid with at least about 2.5% as lipid-bound sialic acid, all of which are provided in whole or in part from the enriched whey protein concentrate. Also disclosed are methods of accelerating brain development, neural migration, and cognitive development in an infant by administering the infant formulas during the first 2-4 months of life, preferably as a sole source of nutrition.

摘要翻译： 公开了包含至少约6.5g / L的按照饲料计算的富集的乳清蛋白浓缩物，按总脂肪酸的重量计至少约0.13％的二十二碳六烯酸和至少约0.25％的花生四烯酸的婴儿配方， 总脂肪酸的重量。 配方还通常包括至少约5mg / L的神经节苷脂，至少约150mg / L的磷脂，和至少约70mg / L的总唾液酸，至少约2.5％的脂质结合的唾液酸， 所有这些全部或部分来自富集的乳清蛋白浓缩物。 还公开了通过在生命的前2-4个月内通过施用婴儿配方来优化作为唯一的营养来源来加速婴儿的脑发育，神经迁移和认知发育的方法。

公开(公告)号：US20080057178A1

公开(公告)日：2008-03-06

申请号：US11771435

申请日：2007-06-29

申请人： Ricardo Rueda ,  Alejandro Barranco ,  Maria Ramirez ,  Enrique Vazquez ,  Eduardo Valverde ,  Pedro Prieto ,  Margaret Dohnalek

发明人： Ricardo Rueda ,  Alejandro Barranco ,  Maria Ramirez ,  Enrique Vazquez ,  Eduardo Valverde ,  Pedro Prieto ,  Margaret Dohnalek

IPC分类号： A23J1/20 ,  A23L1/305

CPC分类号： A23L33/40

摘要： Disclosed are infant formulas comprising, on an as-fed basis (A) at least about 5 mg/L of gangliosides, (B) at least about 150 mg/L of phospholipids, (C) lactoferrin, and (D) at least about 70 mg/L of sialic acid, with at least about 2.5% by weight of the sialic acid as lipid-bound sialic acid. From about 50% to 100% by weight of each of the gangliosides, phospholipids, lactoferrin, and sialic acid is provided by an enriched whey protein concentrate, with the concentrate representing at least about 6.5 g/L of the formula on an as-fed basis. Also disclosed are methods of using the formula to reduce the risk of diarrhea infants, and to produce a gut microflora profile similar to that of breast-fed infants.

摘要翻译： 公开了婴儿配方，其包含基于（A）至少约5mg / L的神经节苷脂，（B）至少约150mg / L的磷脂，（C）乳铁蛋白和（D）至少约 70mg / L的唾液酸，至少约2.5重量％的唾液酸作为脂质结合的唾液酸。 通过富集的乳清蛋白浓缩物提供每种神经节苷脂，磷脂，乳铁蛋白和唾液酸的约50重量％至100重量％，浓缩物表示至少约6.5g / L的配方， 基础。 还公开了使用该配方降低腹泻婴儿风险的方法，以及产生与母乳喂养婴儿相似的肠道微生物群落谱。

公开(公告)号：US20080003330A1

公开(公告)日：2008-01-03

申请号：US11479621

申请日：2006-06-30

申请人： Ricardo Rueda ,  Alejandro Barranco ,  Maria Ramirez ,  Enrique Vazquez ,  Eduardo Valverde ,  Pedro Prieto ,  Margaret H. Dohnalek

发明人： Ricardo Rueda ,  Alejandro Barranco ,  Maria Ramirez ,  Enrique Vazquez ,  Eduardo Valverde ,  Pedro Prieto ,  Margaret H. Dohnalek

IPC分类号： A23L1/30

CPC分类号： A61K33/00 ,  A23L33/12 ,  A23L33/19 ,  A23L33/40 ,  A61K31/202 ,  A61K31/28 ,  A61K31/685 ,  A61K31/7008 ,  A61K31/7032 ,  A61K38/00 ,  A61K45/06

摘要： Disclosed are infant formulas comprising fat, protein, carbohydrate, vitamins, and minerals, including on an as-fed basis, at least about 5 mg/L of gangliosides, at least about 150 mg/L of phospholipids, at least about 70 mg/L of total sialic acid with at least about 2.5% as lipid-bound sialic acid, at least about 0.13% docosahexaenoic acid by weight of total fatty acids, and at least about 0.25% arachidonic acid by weight of total fatty acids. Also disclosed are methods of accelerating brain development, neural migration, and cognitive development in an infant by administering the infant formulas during the first 2-4 months of life, preferably as a sole source of nutrition.

摘要翻译： 公开了包含脂肪，蛋白质，碳水化合物，维生素和矿物质的婴儿配方，包括以按原料计，至少约5mg / L的神经节苷脂，至少约150mg / L的磷脂，至少约70mg / L的总唾液酸，其具有至少约2.5％的脂质结合的唾液酸，按总脂肪酸的重量计至少约0.13％的二十二碳六烯酸，以及总脂肪酸的至少约0.25％的花生四烯酸。 还公开了通过在生命的前2-4个月内通过施用婴儿配方来优化作为唯一的营养来源来加速婴儿的脑发育，神经迁移和认知发育的方法。

公开(公告)号：US20050085441A1

公开(公告)日：2005-04-21

申请号：US10797730

申请日：2004-03-10

申请人： James Leach ,  Stacey Borowicz ,  Pedro Prieto ,  Balbino Alarcon ,  Ricardo Rueda ,  Enrique Vazquez

发明人： James Leach ,  Stacey Borowicz ,  Pedro Prieto ,  Balbino Alarcon ,  Ricardo Rueda ,  Enrique Vazquez

IPC分类号： A61K31/715

CPC分类号： A61K31/715

摘要： The subject invention relates to monovalent oligosaccharides and their use, for example, in the treatment and prevention of mammalian disease caused by HIV-1 virus infections. In particular, the oligosaccharides globotriose and lactose may be used alone or in combination to competitively inhibit the formation of the viral fusion complex that occurs upon infection.

摘要翻译： 本发明涉及一价低聚糖及其用于治疗和预防HIV-1病毒感染引起的哺乳动物疾病的用途。 特别地，寡糖球三糖和乳糖可以单独使用或组合使用，以竞争性地抑制感染时发生的病毒融合复合物的形成。

公开(公告)号：US20080003329A1

公开(公告)日：2008-01-03

申请号：US11479504

申请日：2006-06-30

申请人： Ricardo Rueda ,  Alejandro Barranco ,  Maria Ramirez ,  Enrique Vazquez ,  Eduardo Valverde ,  Pedro Prieto ,  Margaret H. Dohnalek

发明人： Ricardo Rueda ,  Alejandro Barranco ,  Maria Ramirez ,  Enrique Vazquez ,  Eduardo Valverde ,  Pedro Prieto ,  Margaret H. Dohnalek

IPC分类号： A23L1/30

CPC分类号： A23L33/40

摘要： Disclosed are infant formulas comprising fat, protein, carbohydrate, vitamins, and minerals, including on an as-fed basis (A) at least about 5 mg/L of gangliosides, (B) at least about 150 mg/L of phospholipids, and (C) lactoferrin, and (D) at least about 70 mg/L of sialic acid, with at least about 2.5% by weight of the sialic acid as lipid-bound sialic acid. Also disclosed are methods of using the formula to reduce the risk of diarrhea infants, and to produce a gut microflora profile similar to that of breast-fed infants.

摘要翻译： 本发明公开了包含脂肪，蛋白质，碳水化合物，维生素和矿物质的婴儿配方，包括至少约5mg / L的神经节苷脂，（B）至少约150mg / L的磷脂，以及 （C）乳铁蛋白，和（D）至少约70mg / L的唾液酸，至少约2.5重量％的唾液酸作为脂质结合的唾液酸。 还公开了使用该配方降低腹泻婴儿风险的方法，以及产生与母乳喂养婴儿相似的肠道微生物群落谱。